Fate Therapeutics Inc (FATE)

[jondoeuk]

Encouraging start. I hope they present additional data at ASH. I know NKTX could (or at an investor event) on their anti-CD19 CAR-NK (+/- anti-CD20 mAb) in patients who have failed prior CAR-T therapy.

Also, FATE's trial testing FT522 (+ anti-CD20 mAb) either with or without LD chemo should be underway later this year. It builds on FT596 with CD38 knockout and an alloimmune defence receptor https://www.globenewswire.com/news-release/2021/12/13/2351194/0/en/Fate-Therapeutics-Showcases-Positive-Interim-Phase-1-Data-from-FT596-Off-the-shelf-iPSC-derived-CAR-NK-Cell-Program-for-Relapsed-Refractory-B-cell-Lymphoma-at-2021-ASH-Annual-Meeti.html